RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $141

Benzinga Newsdesk www.benzinga.com Positive 90.2%

Neg 0% Neu 0% Pos 90.2%

RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $137 to $141.